Fenebrutinib is a Small Molecule owned by Genentech USA, and is involved in 17 clinical trials, of which 12 were completed, and 5 are ongoing.

Fenebrutinib (GDC-0853, RG-7845) inhibits Bruton's tyrosine kinase (BTK) which is implicated in the development of diseases. It blocks the autophosphorylation of BTK. BTK functions downstream of multiple receptors including growth factors, chemokine, and innate immune receptors and initiates a diverse range of cellular processes, such as cell proliferation, survival, differentiation, motility, angiogenesis, cytokine production, and antigen presentation. These processes may play a pivotal role in the development and progression of diseases. The drug candidate may exhibit therapeutic intervention by checking the underlying cause of disease progression.

The revenue for Fenebrutinib is expected to reach a total of $2.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Fenebrutinib NPV Report.

Fenebrutinib is originated and owned by Genentech USA. F. Hoffmann-La Roche is the other company associated in development or marketing of Fenebrutinib.

Fenebrutinib Overview

Fenebrutinib (GDC-0853, RG-7845) is under development for the treatment of B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, indolent lymphoma, follicular lymphoma, relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS). It is administered orally. The drug candidate is a second generation Bruton's tyrosine kinase (BTK) inhibitor. It is a new molecular entity. It was also under development for the treatment of systemic lupus erythematosus, rheumatoid arthritis and chronic spontaneous urticaria.

F. Hoffmann-La Roche Overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.

Quick View – Fenebrutinib

Report Segments
  • Innovator
Drug Name
  • Fenebrutinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Dermatology
  • Immunology
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.